BE902626A - NEW DELAYED GALEINIC FORM. - Google Patents

NEW DELAYED GALEINIC FORM.

Info

Publication number
BE902626A
BE902626A BE1/011271A BE1011271A BE902626A BE 902626 A BE902626 A BE 902626A BE 1/011271 A BE1/011271 A BE 1/011271A BE 1011271 A BE1011271 A BE 1011271A BE 902626 A BE902626 A BE 902626A
Authority
BE
Belgium
Prior art keywords
matrix
galeinic
water
agent
new delayed
Prior art date
Application number
BE1/011271A
Other languages
French (fr)
Original Assignee
Sandoz Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Sa filed Critical Sandoz Sa
Publication of BE902626A publication Critical patent/BE902626A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention a pour objet une dispersion solide d'un agent ayant une activité pharmacologique, dans un matrice cristalline soluble dans l'eau servant d'excipient, caractérisée en ce que l'agent : a) a une solublilité maximale dans l'eau de 0,01% à 37 degrés C, b) est présent dans la matrice à une concentration supérieure à 5 % en poids, c) est présent dans la matrice à une concentration supérieure à 5 % en poids sous une forme cristalline cohérente. Structure secondaire d'un agent actif résultant de l'extraction de la matrice, par exemple avec de l'eau.The subject of the invention is a solid dispersion of an agent having pharmacological activity, in a water-soluble crystalline matrix serving as an excipient, characterized in that the agent: a) has maximum solubility in water 0.01% at 37 degrees C, b) is present in the matrix at a concentration greater than 5% by weight, c) is present in the matrix at a concentration greater than 5% by weight in a coherent crystalline form. Secondary structure of an active agent resulting from the extraction of the matrix, for example with water.

BE1/011271A 1984-06-14 1985-06-10 NEW DELAYED GALEINIC FORM. BE902626A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3422083 1984-06-14
DE3442566 1984-11-22

Publications (1)

Publication Number Publication Date
BE902626A true BE902626A (en) 1985-12-10

Family

ID=25822108

Family Applications (1)

Application Number Title Priority Date Filing Date
BE1/011271A BE902626A (en) 1984-06-14 1985-06-10 NEW DELAYED GALEINIC FORM.

Country Status (21)

Country Link
AT (1) AT391806B (en)
AU (2) AU587190B2 (en)
BE (1) BE902626A (en)
CA (1) CA1264441A (en)
CY (1) CY1635A (en)
DE (1) DE3520184C2 (en)
DK (1) DK167649B1 (en)
ES (1) ES8702141A1 (en)
FR (1) FR2565822B1 (en)
GB (3) GB2160100B (en)
GR (1) GR851430B (en)
HK (1) HK25192A (en)
HU (1) HU198844B (en)
IE (1) IE58834B1 (en)
IL (1) IL75490A0 (en)
IT (1) IT1200080B (en)
LU (1) LU85946A1 (en)
NL (1) NL194389C (en)
NZ (1) NZ212390A (en)
PT (1) PT80635B (en)
SE (1) SE504583C2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187751B (en) * 1985-10-15 1987-12-23 Eurand Spa PROCEDURE FOR THE PREPARATION OF SOLID FORMULATIONS OF NIFEDIPINE WITH HIGH BIO AVAILABILITY AND WITH PROLONGED EFFECT AND FORMULATIONS SO OBTAINED
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
EP0406315B1 (en) * 1988-03-24 1992-11-11 Bukh Meditec A/S Controlled release composition
GR1000270B (en) * 1988-09-30 1992-05-12 Alza Corp Dose for cardiovascular troubles therapy
DK469989D0 (en) * 1989-09-22 1989-09-22 Bukh Meditec PHARMACEUTICAL PREPARATION
MX9300110A (en) * 1992-01-13 1994-07-29 Gerhard Gergely PHARMACEUTICAL PREPARATION IN THE FORM OF AN EFFERVESCENCE OR DISINTEGRATION TABLET OR OF AN INSTANT-TYPE GRANULATE AND PROCEDURE FOR ITS PREPARATION.
DE4201179A1 (en) * 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Granulates or pellets comprising dispersion of active agent in hydrophilic macromolecules - are e.g. for treatment of depression, hypertension, rheumatism, etc.
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
US6093420A (en) 1996-07-08 2000-07-25 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
DE19710009A1 (en) * 1997-03-12 1998-09-24 Knoll Ag Multi-phase preparation forms containing active ingredients
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6787157B1 (en) 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
WO2000076480A2 (en) * 1999-06-11 2000-12-21 Eli Lilly And Company Pharmaceutical materials and methods for their preparation and use
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
ATE324909T1 (en) * 1999-08-04 2006-06-15 Astellas Pharma Inc STABLE MEDICAL COMPOSITIONS FOR ORAL ADMINISTRATION USING IRON OXIDES
JP3893058B2 (en) 1999-09-30 2007-03-14 ペンウェスト ファーマシューティカルズ カンパニー Sustained release matrix system for highly soluble drugs
EP1368006B1 (en) * 2001-02-13 2006-05-03 AstraZeneca AB Novel modified released formulation
US7135436B2 (en) 2003-05-05 2006-11-14 J.F. Daley International, Ltd. Solid algicide, preparation and usage in recirculating water
EP1690528A1 (en) 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Process for the preparation of dosage forms comprising a solid dispersion of a microcrystalline active agent
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
CA2670749A1 (en) 2006-12-05 2008-06-12 Landec Corporation Drug delivery
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
CN102271661A (en) * 2008-08-20 2011-12-07 德克萨斯州立大学董事会 Hot-melt extrusion of modified release multi-particulates

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617362A1 (en) * 1967-11-17 1971-03-25 Beiersdorf Ag Process for the production of medicaments with delayed release of active substances in the form of capsules
DE2400819C2 (en) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Process for the production of solid preparations of poorly soluble active pharmaceutical ingredients in extremely fine distribution
DE2546577B2 (en) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Solid substances made from polyvinylpyrrolidone and ergot alkaloids
GB1504553A (en) * 1975-11-17 1978-03-22 Sandoz Ltd Tablet formulations
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
DK149855C (en) * 1977-06-20 1987-04-21 Sandoz Ag METHOD OF ANALOGY FOR THE PREPARATION OF 1,4-DIHYDROPYRIDINE DERIVATIVES
CH639659A5 (en) * 1978-12-18 1983-11-30 Sandoz Ag NEW 1,4-DIHYDROPYRIDINE DERIVATIVES, THEIR PRODUCTION AND USE.
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
DK154607C (en) * 1978-12-21 1989-06-05 Sandoz Ag PROCEDURE FOR PREPARING A PHARMACEUTICAL FORM FOR ORAL ADMINISTRATION OF ERGOTAL KALOIDS
DE2904310A1 (en) * 1979-02-05 1980-08-07 Boehringer Mannheim Gmbh MOLDINGS WITH RETARDED ACTIVE SUBSTANCE RELEASE AND METHOD FOR THE PRODUCTION THEREOF
JPS56115726A (en) * 1980-02-20 1981-09-11 Kaken Pharmaceut Co Ltd Pharmaceutical containing nifedipine
DE3033919A1 (en) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen SOLID PHARMACEUTICAL PREPARATIONS CONTAINING NIFEDIPINE AND METHOD FOR THE PRODUCTION THEREOF
US4442112A (en) * 1981-09-02 1984-04-10 Sandoz Ltd. Dihydropyridine derivatives useful in treating vascular headaches
EP0078430B2 (en) * 1981-10-29 1993-02-10 Bayer Ag Process for preparing solid fast-releasing drug formulations of dihydropyridines
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
DE3318649A1 (en) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen TWO-PHASE FORMULATION

Also Published As

Publication number Publication date
GR851430B (en) 1985-11-25
IT8548210A0 (en) 1985-06-13
AT391806B (en) 1990-12-10
IE58834B1 (en) 1993-11-17
GB2196851A (en) 1988-05-11
DK264785D0 (en) 1985-06-12
GB2196852B (en) 1989-05-17
CY1635A (en) 1992-11-06
ES8702141A1 (en) 1987-01-01
AU4454389A (en) 1990-03-22
CA1264441A (en) 1990-01-16
GB8727055D0 (en) 1987-12-23
GB2196851B (en) 1989-06-07
HU198844B (en) 1989-12-28
HK25192A (en) 1992-04-10
SE8502950D0 (en) 1985-06-13
FR2565822B1 (en) 1989-02-17
ATA174885A (en) 1990-06-15
DE3520184C2 (en) 1997-03-13
GB2196852A (en) 1988-05-11
IE851460L (en) 1985-12-14
LU85946A1 (en) 1986-01-24
NL194389B (en) 2001-11-01
IL75490A0 (en) 1985-10-31
DK167649B1 (en) 1993-12-06
ES544075A0 (en) 1987-01-01
SE8502950L (en) 1985-12-15
SE504583C2 (en) 1997-03-10
IT1200080B (en) 1989-01-05
PT80635A (en) 1985-07-01
GB2160100A (en) 1985-12-18
GB8514855D0 (en) 1985-07-17
AU4348685A (en) 1985-12-19
NZ212390A (en) 1992-02-25
NL8501578A (en) 1986-01-02
DE3520184A1 (en) 1985-12-19
AU587190B2 (en) 1989-08-10
GB8727056D0 (en) 1987-12-23
DK264785A (en) 1985-12-15
HUT40918A (en) 1987-03-30
GB2160100B (en) 1989-06-01
FR2565822A1 (en) 1985-12-20
NL194389C (en) 2002-03-04
PT80635B (en) 1987-10-20

Similar Documents

Publication Publication Date Title
BE902626A (en) NEW DELAYED GALEINIC FORM.
KR840000236A (en) How to minimize water loss in topical formulations in mammals
IE39898B1 (en) 1-or 7-oxoalkyl xanthine derivatives
FR2426731A1 (en) AQUEOUS AND CONCENTRATED TENSIO-ACTIVE COMPOSITIONS
BE899779A (en) SINGLE PHASE LIQUID DETERGENT COMPOSITION, STABILIZED, LOADED WITH DETERGENT ADJUVANT AND CONTAINING ENZYMES.
Mandl et al. Epinephrine and glucagon counteract inhibition of protein synthesis induced by D-galactosamine in isolated mouse hepatocytes
ES461077A1 (en) 2-(Nuclearly-substituted)benzylpyrrolidines
DE3277731D1 (en) Solid, strong alcaline compounds that contain active chlorine
MY101902A (en) Novel galenical retard form
JPS5519204A (en) Production of inorganic acid salt of guanidine
JPS5429102A (en) Impeller of pump with high water head
JPS51146422A (en) Preparation of sulfochloride
Rastogi et al. Nucleic acid and protein content of the frog pars distalis and hypothalamus during the annual reproductive cycle
ES8500897A1 (en) Amine oxide formulations.
Shelaev Reduction of the End Waste When Manufacturing Rectangular Forgings
JPS52120911A (en) Prevention of crack at grain boundary at high temperature
FR2394575A1 (en) EXPANDABLE POLYSTYRENE PARTICLES AND METHOD OF PREPARATION
JPS5616699A (en) Electrolytic polishing method for austenitic stainless steel containing nickel and nickel base alloy by neutral electrolyte
Cupr et al. Electrochemical Protection of Structural Steels
Cheesewright EEC Steel Output Rises Only 1% in First Half of Year.(1985)
IT8219292A0 (en) PROCEDURE FOR CASTING STEEL, PARTICULARLY STEEL INGOTS.
JPS5337664A (en) Preparation of 5-benzylhydantion
TANAKA et al. Effects of Some Food Additives on Protein Biosynthesis by Rat Liver Slice and Cell-Free System (Part 2)
JPS5277079A (en) Preparation of spiro compound
Hilgenfeldt et al. Some Aspects of the Increased Use of Secondary Aluminum Alloys for Pressure Die Casting

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *NOVARTIS A.G.

Effective date: 20050610

RE20 Patent expired

Owner name: *NOVARTIS A.G.

Effective date: 20050610